ProKidney combination with Social Capital Suvretta Holdings Corp. III
We are advising ProKidney on the transaction
Experience
To find Davis Polk deals and cases of particular interest, select filters based on practice, industry, region, lawyer and keyword.
Filters
Biodesix $50 million at-the-market offering
The shares are listed on the Nasdaq Global Market
Legend Biotech $345 million follow-on offering
The shares are listed on the Nasdaq Global Select Market
Dynamics Special Purpose $601 million combination with Senti Biosciences
We are advising Dynamics, a SPAC, on the transaction
BeiGene RMB22.2 billion Shanghai IPO
The offering, equivalent to $3.5 billion, is the largest biotech IPO to date in 2021
Yonghe HK$1.49 billion IPO
The shares are listed on the HKEX
Merck $8 billion notes offering, including its debut sustainability debt
The offering includes five tranches of notes
CANbridge Pharmaceuticals HK$685 million IPO
We advised CANbridge Pharmaceuticals on its IPO and HKEX listing
Olympus $500 million senior notes offering
The debut offering consisted of 2.143% senior notes due 2026
Privia Health $174 million secondary offering
We advised Privia on its SEC-registered offering of stock